— Bio-Path Holdings Inc. (NASDAQ: BPTH) reported a loss of $3.24 share for the full year 2019, narrower than a loss of $14.38 per share in the previous year.
— Research and development expenses remained flat from the last year at $4.6 million.
— General and administrative expenses were $4.1 million during the year ended December 31, 2019, up 21% from last year, primarily due to increased legal fees and salaries and benefits expense.
— The company is in the process of initiating a phase 1 study of second pipeline candidates in the first half of this year to evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients.
— The company is nearing completion of an investigational new drug (IND)-enabling studies of BP1003 for the treatment of solid tumors, including pancreatic cancer, and expects to file an IND application for phase 1 study in 2020.
— Following the successful completion of the safety testing in Stage 2 of phase 2 clinical trial of prexigebersen in acute myeloid leukemia (AML), the company now plans to advance this program to its next stage in the first half of 2020.
— The company filed an IND application for prexigebersen in the treatment of solid tumors including ovarian and endometrial cancer and expects to start that study later this year.
Most Popular
AMAT Stock: Is now the right time to invest in Applied Materials?
It is estimated that the size of the global chip manufacturing equipment market would nearly double from the current levels to about $142 billion in the next eight years. Applied
Here’s a look at Take-Two Interactive Software’s (TTWO) expectations for the coming year
Shares of Take-Two Interactive Software (NASDAQ: TTWO) were down over 2% on Friday. The stock has dropped 32% year-to-date and 35% over the past 12 months. Earlier this week, the
Beyond short-term challenges, Cisco’s (CSCO) prospects remain intact
Cisco Systems Inc. (NASDAQ: CSCO) is the undisputed leader in networking technology, but its core business has been facing challenges over the past few years. While the company faces stiff
